BioTime Company Profile (NYSEMKT:BTX)

Analyst Ratings

Consensus Ratings for BioTime (NYSEMKT:BTX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.50

Analysts' Ratings History for BioTime (NYSEMKT:BTX)
Show:
DateFirmActionRatingPrice TargetActions
4/7/2016Chardan CapitalInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for BioTime (NYSEMKT:BTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q4($0.17)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.14)$0.61 million$1.07 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioTime (NYSEMKT:BTX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for BioTime (NYSEMKT:BTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioTime (NYSEMKT:BTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioTime (NYSEMKT:BTX)
DateHeadline
07/27/16 11:32 AMBioTime, Inc. to Report Second Quarter Results on August …
07/27/16 08:08 AMBioTime, Inc. to Report Second Quarter Results on August 9, 2016 - [at noodls] - ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 27, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it ...
07/21/16 03:04 PMBioTime Inc (AMEX:BTX) Stock Volatility Hits An Unsually High Level - CML News
07/21/16 12:50 PMETF’s with exposure to BioTime, Inc. : July 21, 2016 -
07/20/16 04:03 PMBiotime Incorporated (NYSEMKT:BTX) Shorts Decreased by 26.35% After Short Covering - Consumer Eagle
07/20/16 04:03 PMIncreased Stock Volatility Watch: BioTime, Inc. (:BTX) - Engelwood Daily
07/20/16 09:04 AMCorporate Document-Investor Presentation for BioTime, Inc. -
07/16/16 02:58 PMBiotime Incorporated (NYSEMKT:BTX) Shorts Decreased by 2.42% After Short Covering - Consumer Eagle
07/14/16 02:48 PMLandmark Stem Cell Clinical Trial Procedure Performed at Santa Clara Valley Medical Center - [at noodls] - Santa Clara County, CA. Last week, physicians at Santa Clara Valley Medical Center (SCVMC), in partnership with Stanford Medicine, successfully completed a surgery injecting stem cells into the spinal ...
07/14/16 10:32 AMBiotime Incorporated (NYSEMKT:BTX) Short Interest Decreased By 2.42% - Consumer Eagle
07/14/16 10:32 AMInsiders Increasing Positions in: BioTime, Inc. (:BTX) - Press Telegraph
07/10/16 02:54 PMBiotime Incorporated (NYSEMKT:BTX) Shorts Decreased by 2.42% After Short Covering - Press Telegraph
07/08/16 10:58 AMBioTime, Inc. Stock Momentum at Critical Inflection Point - CML News
07/08/16 10:58 AMToday's Watch List: BioTime, Inc. (NYSEMKT:BTX), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), Gran Tierra Energy ... - KC Register
07/07/16 02:59 PMStock Tracking Down This Month; Investor Alert on BioTime, Inc. (:BTX) - Engelwood Daily
07/07/16 01:46 PMETF’s with exposure to BioTime, Inc. : July 7, 2016 -
07/05/16 04:23 PMBIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/05/16 02:59 PMBioTime, Inc. Announces Full Exercise and Closing of Underwriters' Over-Allotment Option - Business Wire (press release)
07/05/16 10:51 AMBioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option - [at noodls] - BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option The text version of this document is not available at the moment. The original content was posted at original link ...
07/05/16 07:44 AMBiotime Incorporated (NYSEMKT:BTX) Short Interest Decreased By 2.42% - Engelwood Daily
07/01/16 11:04 AMBioTime : Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering
06/30/16 08:28 PMBioTime, Inc. Stock Price Increases Today - Engelwood Daily
06/30/16 08:28 PMMorning Buzz: WPX Energy, Inc. (NYSE:WPX), BioTime, Inc. (NYSEMKT:BTX), Newmont Mining Corporation (NYSE ... - KC Register
06/29/16 08:04 PMBioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual ... - Business Wire (press release)
06/29/16 07:21 AMBioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering - [at noodls] - - Deep Learning Algorithms have the potential to unlock mechanisms of tissue regeneration for applications in age-related disease - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 29, 2016-- BioTime, Inc. (NYSE ...
06/26/16 08:10 AMAnalysts Review: BioTime, Inc. (NYSEMKT:BTX) - iStreetWire
06/22/16 03:08 PMBioTime, Inc. Announces Closing of Public Offering of Common Stock - Business Wire (press release)
06/21/16 11:19 AMBioTime, Inc. Announces Closing of Public Offering of Common Stock - [at noodls] - BioTime, Inc. Announces Closing of Public Offering of Common Stock The text version of this document is not available at the moment. The original content was posted at original link . BioTime Inc. published ...
06/20/16 09:24 AMHealthcare Unusual Volume: ViewRay, Inc. (NASDAQ:VRAY), BioTime, Inc. (NYSEMKT:BTX), Innocoll Holdings plc ... - KC Register
06/18/16 07:39 AMBioTime Inc. (BTX) Drops 7.69% on June 16 - Equities.com
06/17/16 02:51 PMBioTime, Inc. (NYSEMKT:BTX) Eyes $17.5 Million IPO - Scibility Media
06/17/16 01:13 PMBIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
06/16/16 08:19 PMBioTime (BTX) Prices 7.3M Stock Offering at $2.39/Share
06/16/16 02:57 PMBiggest Movers in Manufacturing Stocks Now – QLGC VBIV BLPH AMD - Investorplace.com
06/16/16 02:57 PMBioTime (BTX) Prices 7.3M Stock Offering at $2.39/Share - StreetInsider.com
06/16/16 11:08 AMA Look at Five Stocks that Are Trending on Thursday -
06/16/16 09:39 AMBioTime, Inc. Announces Pricing of Public Offering of Common Stock - [at noodls] - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 16, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative ...
06/16/16 07:21 AMAfter-Hours Stock Movers 06/15: (QLGC) (RLYP) (NUS) Higher; (EVHC) (BTX) (KFY) Lower (more...) - StreetInsider.com
06/16/16 07:21 AMBioTime, Inc. Announces Proposed Public Offering of Common Stock - Business Wire (press release)
06/15/16 04:19 PMBIOTIME INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 03:19 PMBioTime, Inc. Announces Proposed Public Offering of Common Stock - [at noodls] - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative ...
06/13/16 03:16 PMToday's Hot List: Corium International, (NASDAQ:CORI), BioTime, (NYSEMKT:BTX), Discovery Communications ... - KC Register
06/13/16 03:16 PMBioTime (BTX), Cell Cure Receive DSMB Approval to Move Forward with OpRegen Phase 1/2a Enrollment - StreetInsider.com
06/13/16 10:58 AMBiotime to up dosage for OpRegen in phase I/II trial
06/13/16 06:19 AMBioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD - [at noodls] - BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD - Safety Confirmed with No Concerns Reported in Cohort 1 - - Approval to ...
06/10/16 11:29 AMBioTime (BTX) Unit Receives $2.2M Grant for Development of OpRegen in Dry-AMD - StreetInsider.com
06/10/16 11:29 AMBioTime Inc. (BTX) is Trading Higher on Unusual Volume for June 08 - Equities.com
06/10/16 08:49 AMBioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program - [at noodls] - - Israel Innovation Authority awards a grant to Cell Cure Neurosciences, a BioTime Subsidiary, that will support ongoing development of OpRegen®, to address a leading cause of blindness, dry-AMD - This ...
06/09/16 11:34 AMBioTime to Present at the Jefferies 2016 Global Healthcare Conference - Digital Journal
06/09/16 06:19 AMBioTime to Present at the Jefferies 2016 Global Healthcare Conference - [at noodls] - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 9, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the ...

Social

About BioTime

BioTime logoBioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company's pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient's own somatic or adult stem cells, at the desired location.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NYSEMKT
  • Symbol: BTX
  • CUSIP: 09066L10
Key Metrics:
  • Previous Close: $3.00
  • 50 Day Moving Average: $2.71
  • 200 Day Moving Average: $2.68
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $280.31M
  • Beta: 1.31
  • Current Year EPS Consensus Estimate: $-0.69 EPS
  • Next Year EPS Consensus Estimate: $-0.48 EPS
Additional Links: